Vaxcyte (PCVX) reported a full-year 2024 net loss late Tuesday of $3.80 per diluted share, narrower than a per-share loss of $4.14 a year earlier.

Analysts polled by FactSet expected a per-share loss of $3.91.

The company said it had cash, cash equivalents and investments of $3.13 billion as of Dec. 31, up from $1.24 billion a year earlier. Vaxcyte said the increase was mainly due to $2.2 billion in net proceeds from two follow-on financings last year.